TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, has on Monday announced an investment, from its TVM Healthcare Afiyah Fund, of EUR 10 million ($10.82 million) into DEBx Medical, an Amsterdam-based medical devices company.

TVM Capital Healthcare said in a statement that its investment in DEBx Medical will enable the company to commence commercialization of its groundbreaking product for the benefit of patients.

As part of the firm’s investment, DEBx Medical will establish a regional headquarter and a production base in MENA, thereby accelerating the introduction of its innovative wound care solution to the region.

DEBx Medical, founded in 2019, is a firm aims to support doctors and their patients from diagnosis through treatment, follow-up care and maintenance of a healthy wound bed.

The firm was founded in 2019 by Chief Executive Officer Bert Quint, Prof. Dr. Carlo Bignozzi and Managing Director Alberto Cogo with the aim to develop and provide a single treatment to eliminate wound infection in a market that has not seen significant innovation in the last two decades.

The firm has developed a groundbreaking product, DEBRICHEM®, which offers a superior alternative to existing treatments for non-healing chronic wounds.

This innovative product is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds.

With CE and ISO approvals obtained in February 2021, DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market.

Chronic wounds pose a significant healthcare challenge, affecting approximately 2.4 percent of the population throughout their lifetime, and is particularly pronounced in the Gulf Cooperation Council (GCC) countries, where high levels of diabetes contribute to the problem.

Hard-to-heal wounds have the potential for poor patient health and quality of life outcomes and represent a substantial cost to healthcare systems.

“With this investment from our TVM Healthcare Afiyah Fund, we will accelerate the market introduction of a product which will transform the management of chronic wounds, and improve the life of millions of patients,” said Tristan de Boysson, Managing Partner of TVM Capital Healthcare.

According to him, this investment is also part of the firm fund’s strategy of bringing innovative, best-in-class healthcare solutions to the wider Middle East and North Africa (MENA) region.

“We are looking forward to working together with the DEBx Medical management team,” he said.

Bert Quint, Co-founder and Chief Executive Officer of DEBx Medical said the firm founded the company with the aim of innovating wound care, a market that has not seen significant innovation in a very long time.

“Our product, DEBRICHEM®, has the potential to disrupt the chronic wound care market and help patients to heal fast, safely and effectively. After just one single treatment, more than 90 percent of chronic wounds start healing,

“TVM Capital Healthcare’s investment is testament to our technology, and we are looking forward to bringing our product to market together,” he said.

Singapore HealthTech platform Speedoc closes $28M Pre-Series B Round